MAPT and Alzheimer disease: There are limitations in the study by Banerjee et al., such as small sample size of AD subjects, lack of sufficient tau and Aβ biomarkers, atypical AD patient phenotypes and a limited amount of contaminated Aβ-40 in archived HWP c-hGH samples [21,22].